Captain T Cell Raises €8.5M in Seed Funding for Clinical Trials and Platform Development

Captain T Cell's Seed Funding and Progress

Key Highlights:

• Seed Funding: Raised €8.5M in seed funding from investors including i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH, and HIL-INVENT Ges.m.b.H.
• Lead Program Advancement: Funds will be used to further progress Captain T Cell's lead program towards clinical trials.
• Allogeneic Platform Development: Development of a novel allogeneic platform for off-the-shelf treatments of solid tumors.

Captain T Cell's Target Market

• Target Market: Focus on developing T cells for the treatment of solid tumors that are not addressed by existing therapies.
• Biotechnology and Pharmaceutical Companies: Potential partners for collaboration in the development and commercialization of T cell therapies.
• Research Institutions and Academia: Collaboration opportunities for further research and development in the field of T cell therapies.

What Captain T Cell Needs to Buy

• Research and Development Partnerships: Collaborations with research institutions and biotech companies for advancing T cell therapies.
• Manufacturing and Supply Chain Solutions: Partnerships with manufacturers for the production of T cell therapies and managing a reliable supply chain.
• Regulatory and Clinical Expertise: Expertise in navigating regulatory requirements and conducting clinical trials for T cell therapies.